Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Combinations in EGFR-mutant NSCLC with Bim Deletion or Low Mutation Abundance
NCT02930954Phase 2Unknown
- Start
- Nov 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, pemetrexed, carboplatin and gemcitabine in non-small cell lung cancer (NSCLC) (3 arms). Primary endpoint: Progression Free Survival at 8 weeks. Status: unknown.
02
Drugs
bevacizumabpemetrexedcarboplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02930954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930954.